Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
HeartFlow operates a non-invasive AI-powered diagnostic platform that analyzes coronary CT scans to generate personalized 3D models of coronary arteries (FFRct analysis), enabling cardiologists to assess blood flow and stenosis severity without invasive catheterization. The company competes in the $8B+ cardiovascular diagnostics market against traditional invasive angiography and stress testing, with FDA clearance and growing Medicare/commercial payor coverage driving adoption. Stock performance hinges on test volume growth, reimbursement expansion, and path to profitability despite current -77% net margins.
HeartFlow generates revenue through per-test service fees (estimated $1,500-$2,500 per FFRct analysis) paid by healthcare providers or insurers. The company's competitive advantage lies in proprietary deep learning algorithms trained on 20,000+ patient datasets, FDA clearance with clinical validation showing 86% diagnostic accuracy, and growing payor coverage including Medicare national coverage determination (NCD) since 2021. Pricing power stems from cost avoidance versus invasive catheterization ($5,000-$15,000 per procedure) and ability to prevent unnecessary interventions. The 75% gross margin reflects high software/AI leverage with minimal variable costs per test, though significant R&D and sales infrastructure investment drives current operating losses.
Quarterly test volume growth rates and sequential acceleration - market expects 35-45% annual volume growth to justify valuation
Payor coverage expansion announcements - new commercial insurance contracts or Medicare coverage expansions drive addressable market
Clinical trial data and peer-reviewed publications validating diagnostic accuracy and clinical outcomes versus invasive alternatives
International market penetration progress - particularly Japan (Terumo partnership), Germany, UK, and China regulatory approvals
Operating margin trajectory and path to profitability - investors monitor cash burn rate and timeline to positive EBITDA
Competitive threats from Siemens Healthineers, Philips, or GE Healthcare entering AI-powered cardiac diagnostics
Reimbursement policy changes - Medicare or commercial payors could reduce FFRct reimbursement rates or tighten coverage criteria, directly impacting unit economics and addressable market
Technological disruption from major medical device OEMs (Siemens, Philips, GE) integrating competitive AI-powered cardiac analysis directly into CT scanners, bypassing third-party service model
Clinical guideline evolution - cardiology society recommendations shifting away from anatomical assessment toward alternative diagnostic pathways could reduce FFRct utilization
Regulatory risk from FDA post-market surveillance requirements or international approval delays in key markets like China
Siemens Healthineers and Philips developing in-house AI cardiac analysis tools bundled with imaging equipment, leveraging installed base relationships
Cleerly Health and other venture-backed competitors offering broader coronary plaque analysis beyond stenosis assessment, potentially capturing cardiologist mindshare
Traditional invasive FFR catheter manufacturers (Philips Volcano, Abbott) defending market share through improved wire-based technologies and bundled pricing
Price competition from international players in Europe and Asia offering lower-cost CT analysis services
Cash burn sustainability - with -$100M operating cash flow against $2B market cap, the company requires continued access to capital markets or path to profitability within 18-24 months based on current burn rate
Equity dilution risk if additional financing rounds needed before reaching breakeven, particularly challenging in higher interest rate environment with compressed growth stock valuations
moderate - Healthcare utilization shows relative GDP resilience, but elective cardiac procedures exhibit cyclical sensitivity during recessions when patients defer non-urgent diagnostics. Hospital capital budgets for new diagnostic technologies contract during economic downturns, potentially slowing adoption. However, the cost-avoidance value proposition (preventing unnecessary $10,000+ catheterizations) strengthens during cost-conscious periods. Medicare/commercial insurance coverage provides demand stability, though high-deductible health plans may cause patient cost-sharing friction during recessions.
Rising interest rates create multiple headwinds: (1) Higher discount rates compress valuation multiples for unprofitable growth companies, particularly impacting 16x P/S stocks with negative cash flow; (2) Hospital systems face increased borrowing costs for capital equipment and IT infrastructure investments, potentially delaying diagnostic technology adoption; (3) Competition for investor capital intensifies as risk-free rates rise, reducing appetite for cash-burning healthcare IT plays. The company's 8.6x current ratio and minimal debt (0.09 D/E) provide insulation from direct financing cost pressure, but equity valuation remains highly rate-sensitive.
Minimal direct credit exposure given B2B healthcare provider customer base with insurance reimbursement backing most revenue. Hospital system financial health matters for technology adoption budgets, but individual test reimbursement flows through established payor channels. The company's own credit profile is strong with 8.6x current ratio and negligible debt, eliminating refinancing risk. However, tightening credit conditions could pressure hospital capital budgets and slow new account acquisition.
growth - The stock attracts growth investors focused on healthcare IT disruption and AI-powered diagnostics, willing to accept negative cash flow and high P/S multiples (16x) in exchange for 44% revenue growth and large addressable market opportunity. The -77% net margin and -$100M cash burn eliminate value and income investors. Institutional healthcare specialists and thematic AI/digital health funds dominate the shareholder base. The recent -21% six-month decline reflects broader growth stock derating and profitability timeline concerns.
high - Small-cap healthcare IT stocks with negative earnings exhibit elevated volatility driven by binary events (payor coverage decisions, clinical trial results, competitive announcements). The -17.6% one-year return and -21% six-month performance demonstrate sensitivity to growth stock sentiment shifts and interest rate moves. Estimated beta above 1.5 based on sector comparables and market cap. Quarterly earnings volatility stems from lumpy hospital contract timing and test volume seasonality.